Oral GLP-1s: The Wegovy Pill, Rybelsus, and Orforglipron

What exists today

The Wegovy tablet (oral semaglutide 25 mg) launched in early 2026: roughly 15% average trial weight loss — at home with injectable semaglutide — behind a strict ritual (empty stomach, ≤4 oz water, 30-minute wait) and a $149/month introductory price before reverting toward the standard $349 structure. Rybelsus remains the diabetes-labeled oral at lower doses. The full breakdown, rules and all: the Wegovy pill, explained.

The second pill arrived: Foundayo, approved April 2026

Orforglipron is no longer coming — it's here: approved as Foundayo on April 1, 2026, the first small-molecule GLP-1, a once-daily pill with no food, water, or timing restrictions, ~12.4% average loss in ATTAIN-1, launched from $149/month self-pay at the lowest dose via LillyDirect ($25 with commercial savings cards; ~$50 Medicare Part D from July 1, 2026), then retail and telehealth. Full guide: Foundayo, explained; what's behind it: retatrutide's phase 3 and the pipeline map. No FDA-approved oral tirzepatide exists or is close — though a compounded sublingual (ODT) lane does: orally disintegrating tablets from compounding pharmacies, with NexLife publishing the market's cleanest ladders (tirzepatide $229→$199, semaglutide $199→$165 by term). ODTs are compounded products with their own absorption-evidence questions — a needle-free option, not an approved-pill equivalent, and not ranked against either.

Pill vs. needle, honestly

Today's trade: the Wegovy tablet matches injectable semaglutide and Foundayo lands a step below it (~12.4%) — neither matches tirzepatide — the weekly injection that wins on efficacy (20.2% vs 13.7%) — and the daily empty-stomach ritual is a real adherence tax against one weekly shot. Where the pill cleanly wins: needle aversion, travel, and (at $149 intro) price against most of the market.